RSS   Newsletter   Contact   Advertise with us

Merck to acquire Themis

Christian Fernsby ▼ | May 27, 2020
Merc announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Themis.
Agreement   Merck
Themis has a broad pipeline of vaccine candidates and immune modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications. In March, Themis joined a consortium together with the Institut Pasteur and The Center for Vaccine Research at the University of Pittsburgh, supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI), to develop a vaccine candidate targeting coronavirus.

Topics: Merck Themis

Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Themis in exchange for an undisclosed cash payment.